Indication
Diabetic Peripheral Neuropathic Pain
The Diabetic Peripheral Neuropathic Pain pipeline: 16 tracked drugs, 4 approved for this indication.
4 approved / phase 42 Phase 31 Phase 2/37 Phase 21 Phase 11 preclinical / unstaged
Compare the share prices of listed companies in Diabetic Peripheral Neuropathic Pain →
Total attributable cost
$56.9B
$9,349/patient
Drug spend
Not yet sourced
All severities · US